BIOMAT Database Logo BIOMAT Database Logo

Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. 1993

M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
University of Miami School of Medicine, Department of Medicine, FL 33101.

OBJECTIVE To evaluate the safety and efficacy of zalcitabine (also known as dideoxycytidine [ddC]) in patients with advanced human immunodeficiency virus (HIV) infection. METHODS Open-label, randomized study. METHODS AIDS Clinical Trials Units, university-affiliated medical centers, and private practice groups. METHODS Patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex who had tolerated zidovudine for 48 weeks or more. METHODS Fifty-nine patients received zidovudine (500 to 1200 mg/d) and 52 patients received zalcitabine (2.25 mg/d). METHODS The primary end points were survival and time to an AIDS-defining event or death. RESULTS Because significantly more patients withdrew from zidovudine therapy, the median duration of treatment was greater in the zalcitabine group than in the zidovudine group (279.0 days compared with 174.5 days; P = 0.001). The estimated 12-month, event-free probabilities were 53% for the zalcitabine group and 57% for the zidovudine group (relative risk, 1.02; 95% CI, 0.5 to 2.2). The estimated 12-month survival rates were 81% for the zalcitabine group and 75% for the zidovudine group (relative risk, 1.39; CI, 0.5 to 3.8). The rate of decline in CD4 lymphocyte counts was significantly slower in the zalcitabine group than in the zidovudine group (-0.08 cells/day compared with -0.17 cells/day). Patients in the zalcitabine group had gained an average of 0.5 kg at week 20 and 0.4 kg at week 24, whereas patients in the zidovudine group had lost an average of 1.8 kg at week 20 and 2.4 kg at week 24 (P = 0.04 and P = 0.05, respectively). Moderate to severe peripheral neuropathy and ulcerative stomatitis occurred in 10 and 9 patients, respectively, in the zalcitabine group. CONCLUSIONS The sample size for this study was smaller than planned, and no differences in survival and clinical end points were found. Slower rates of decline in CD4 lymphocyte counts and weight, however, were noted for the zalcitabine group.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D012044 Regression Analysis Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable. Regression Diagnostics,Statistical Regression,Analysis, Regression,Analyses, Regression,Diagnostics, Regression,Regression Analyses,Regression, Statistical,Regressions, Statistical,Statistical Regressions
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte

Related Publications

M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
May 1995, Archives of internal medicine,
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
October 1993, Annals of internal medicine,
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
January 1995, International journal of STD & AIDS,
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
August 1996, Annals of internal medicine,
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
July 1997, Antiviral therapy,
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
April 1996, Antiviral therapy,
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
December 1996, Antiviral therapy,
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
January 1995, Annals of internal medicine,
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
May 2000, AIDS (London, England),
M A Fischl, and R M Olson, and S E Follansbee, and J P Lalezari, and D H Henry, and P T Frame, and S C Remick, and M P Salgo, and A H Lin, and C Nauss-Karol, and J Lieberman, and W Soo
Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine.
May 1991, JAMA,
Copied contents to your clipboard!